LTBP2 regulates cisplatin resistance in GC cells via activation of the NF- κB2/BCL3 pathway

In conclusion, silencing LTBP2 could effectively inhibit cell proliferation and mitigate cisplatin resistance via the NFKB noncanonical pathway NFKB2 p52/Bcl-3/cyclin D1. These findings propose LTBP2 as a potential therapeutic target for overcoming cisplatin resistance in GC patients.PMID:38577985 | DOI:10.1590/1678-4685-GMB-2023-0231

Source: Mol Biol Cell - April 5, 2024 Category: Molecular Biology Authors: Jun Wang Wenjia Liang Xiangwen Wang Zhao Chen Lei Jiang Source Type: research